August 02, 2022
Oxford, UK and Cleveland, Ohio, USA – The Oxford-Harrington Rare Disease Centre (OHC), a partnership of the University of Oxford and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced its support of a novel treatment for Duchenne muscular dystrophy, a rare neuromuscular disease...
Continue Reading
January 24, 2022
Linda and Les Vinney committed $1.25 million to establish the Linda and Les Vinney Scholar Program at Harrington Discovery Institute's Center for Brain Health Medicine, which will support new treatments for patients living with Alzheimer's disease. The gift also creates the Linda and Les Vinney Acceleration Awards, which will... Continue Reading
January 18, 2022
Four Medicines in Clinical Trials and More in the Pipeline Continue Reading
December 09, 2021
New Orleans, LA – LSU Health New Orleans entered into an exclusive option and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) granting Takeda the exclusive right to develop further a technology invented at LSU Health New Orleans with the aim to discover potential therapeutics to treat rare... Continue Reading
November 16, 2021
CLEVELAND — In 2020, during the height of the COVID-19 Pandemic, Harrington Discovery Institute at University Hospitals put out a call to scientists around the world: Send us your ideas to battle the coronavirus and we may fund your research.They received three hundred applications.All they needed was a fraction of the money... Continue Reading
October 21, 2021
Researchers have discovered an approach that could prevent nerve cells in the brain from deteriorating after a traumatic brain injury (TBI).A research team including scientists with the Geriatric Research Education and Clinical Center at the Louis Stokes Cleveland VA Medical Center identified the approach for preventing nerve... Continue Reading
October 18, 2021
INDIANAPOLIS— A group of researchers led by Indiana University School of Medicine’s , has been awarded a research program project grant (P01) from the National Heart, Lung and Blood Institute. The award amounts to just over $12 million over the next five years and will fund the development of personalized therapeutic... Continue Reading
October 11, 2021
Dystonias are a group of chronic movement–disabling disorders for which highly effective oral medications or disease-modifying therapies are lacking. The availability of an oral drug with disease-modifying potential would transform the current treatment landscape. 2015 Harrington Scholar-Innovator Nicole Calakos, MD, PhD... Continue Reading
October 11, 2021
Metabolic syndrome is a cluster of conditions and includes obesity and can be dangerous as it increases the risk for heart disease, stroke, diabetes and other diseases. A Harrington Discovery Institute research team proves successful use of “anti-obesity” drug in pre-clinical animal models.“The last piece of the puzzle is... Continue Reading
October 11, 2021
Huntington’s Disease (HD) is a fatal neurological disorder caused by a trinucleotide CAG repeat expansion in the N-terminal exon 1 of the huntingtin (Htt) gene. HD manifests as uncontrolled involuntary movements accompanied by progressive motor and cognitive deficits, psychiatric disturbance, and dementia. There is no therapy... Continue Reading
August 19, 2021
Scientists on either side of the Atlantic have teamed up, through the new (OHC), to address unmet needs in rare disease research and deliver “major clinical impact” to patients.And now, the international collaboration between the University of Oxford, in England, and the Harrington Discovery Institute, in Cleveland, Ohio... Continue Reading